Personalised medicine in patients with CUP and solid 'rare cancers'
Research type
Research Study
Full title
Personalised medicine in patients with cancer of unknown primary (CUP) and solid ‘rare cancers’ using the FoundationOne (FM-1) panel and immune check point inhibitors biomarkers
IRAS ID
221980
Contact name
Hendrik-Tobias Arkenau
Contact email
Sponsor organisation
HCA International
Duration of Study in the UK
3 years, 4 months, 1 days
Research summary
The aim of this study to recruit 100 prospective patients with CUP (confirmed via a Multidisciplinary Team Meeting) and 100 prospective patients with solid ‘rare cancers’ (defined by RARECARE working group) and help identifying suitable treatment options using a detailed molecular profile of archival tumour tissue.
The results from the molecular profiling may reveal genetic features typical of a tumour type (e.g. EGFR exon 19 deletion in lung cancer) which will help identifying the primary site of tumour origin or actionable genetic alterations which allow patients to participate in clinical trials involving the use of targeted agents.The genetic and therapuetic implications of each test will be discussed in a Genetic Review Board meeting. Data on the treatment received will be collected in this research project, but any therapeutic intervention (either standard of care or clinical trial) will require an informed consent form which is not part of this research project.
The patient and/or referring physicians will be contacted by the investigators during the follow-up.
Analysis of the data obtained will be performed using descriptive statistics.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
17/LO/0851
Date of REC Opinion
24 May 2017
REC opinion
Unfavourable Opinion